Ignite Creation Date:
2025-12-25 @ 12:35 AM
Ignite Modification Date:
2026-03-14 @ 5:26 PM
Study NCT ID:
NCT06383767
Status:
RECRUITING
Last Update Posted:
2025-06-19
First Post:
2024-04-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Sponsor:
Qilu Pharmaceutical Co., Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
ESG401-301
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None